PCA analysis for Study ST003657

(Analysis AN006007 )

Select 2 or more experimental factors for PCA analysis.
GroupCombined factors (this analysis)
Sample source:U251 | Condition:anti-GLS1 siRNA | Method of exposure:Transfection
Sample source:U251 | Condition:Control | Method of exposure:Direct exposure
Sample source:U251 | Condition:Control | Method of exposure:Transfection
Sample source:U251 | Condition:Control | Method of exposure:Transwell b.End3
Sample source:U251 | Condition:Control | Method of exposure:Transwell b.End3 + iNHA
Sample source:U251 | Condition:Lipofectamine | Method of exposure:Transfection
Sample source:U251 | Condition:PUREG4-LA12-anti-GLS1 siRNA | Method of exposure:Direct exposure
Sample source:U251 | Condition:PUREG4-LA12-anti-GLS1 siRNA | Method of exposure:Transwell b.End3
Sample source:U251 | Condition:PUREG4-LA12-anti-GLS1 siRNA | Method of exposure:Transwell b.End3 + iNHA
Sample source:U251 | Condition:PUREG4-LA12 | Method of exposure:Direct exposure
Sample source:U251 | Condition:PUREG4-LA12 | Method of exposure:Transwell b.End3
Sample source:U251 | Condition:PUREG4-LA12 | Method of exposure:Transwell b.End3 + iNHA
Sample source:U-87MG | Condition:anti-GLS1 siRNA | Method of exposure:Transfection
Sample source:U-87MG | Condition:Control | Method of exposure:Direct exposure
Sample source:U-87MG | Condition:Control | Method of exposure:Transfection
Sample source:U-87MG | Condition:Control | Method of exposure:Transwell b.End3
Sample source:U-87MG | Condition:Control | Method of exposure:Transwell b.End3 + iNHA
Sample source:U-87MG | Condition:Lipofectamine | Method of exposure:Transfection
Sample source:U-87MG | Condition:PUREG4-LA12-anti-GLS1 siRNA | Method of exposure:Direct exposure
Sample source:U-87MG | Condition:PUREG4-LA12-anti-GLS1 siRNA | Method of exposure:Transwell b.End3
Sample source:U-87MG | Condition:PUREG4-LA12-anti-GLS1 siRNA | Method of exposure:Transwell b.End3 + iNHA
Sample source:U-87MG | Condition:PUREG4-LA12 | Method of exposure:Direct exposure
Sample source:U-87MG | Condition:PUREG4-LA12 | Method of exposure:Transwell b.End3
Sample source:U-87MG | Condition:PUREG4-LA12 | Method of exposure:Transwell b.End3 + iNHA

OR

Perform PCA on individual factors (all analyses in study)
  logo